Invesco
PDLI

Invesco’s PDL BioPharma, Inc. PDLI Stock Holding History

Invesco’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-666,925
Closed -$2.1M – 3893
2020
Q3 		$2.1M Buy
666,925
+63,989
+11% +$204K ﹤0.01% 2473
2020
Q2 		$1.75M Sell
602,936
-36,155
-6% -$114K ﹤0.01% 2530
2020
Q1 		$1.8M Sell
639,091
-272,767
-30% -$879K ﹤0.01% 2455
2019
Q4 		$2.96M Sell
911,858
-50,674
-5% -$147K ﹤0.01% 2467
2019
Q3 		$2.08M Sell
962,532
-2,915
-0.3% -$7.79K ﹤0.01% 2615
2019
Q2 		$3.03M Sell
965,447
-281,596
-23% -$913K ﹤0.01% 2472
2019
Q1 		$4.64M Sell
1,247,043
-532,885
-30% -$1.8M ﹤0.01% 2054
2018
Q4 		$5.16M Buy
1,779,928
+209,371
+13% +$575K ﹤0.01% 1929
2018
Q3 		$4.13M Buy
1,570,557
+37,677
+2% +$92.5K ﹤0.01% 2269
2018
Q2 		$3.59M Buy
1,532,880
+4,226
+0.3% +$11.8K ﹤0.01% 2367
2018
Q1 		$4.49M Buy
1,528,654
+1,010,380
+195% +$2.76M ﹤0.01% 2033
2017
Q4 		$1.42M Sell
518,274
-1,274,105
-71% -$3.91M ﹤0.01% 2813
2017
Q3 		$6.08M Sell
1,792,379
-336,805
-16% -$937K ﹤0.01% 1855
2017
Q2 		$5.26M Sell
2,129,184
-256,264
-11% -$589K ﹤0.01% 1924
2017
Q1 		$5.41M Buy
2,385,448
+108,395
+5% +$240K ﹤0.01% 1933
2016
Q4 		$4.83M Sell
2,277,053
-265,957
-10% -$742K ﹤0.01% 2005
2016
Q3 		$8.52M Sell
2,543,010
-355,510
-12% -$1.13M ﹤0.01% 1609
2016
Q2 		$9.1M Sell
2,898,520
-221,060
-7% -$737K ﹤0.01% 1491
2016
Q1 		$10.4M Buy
3,119,580
+59,820
+2% +$186K ﹤0.01% 1417
2015
Q4 		$10.8M Sell
3,059,760
-1,600,554
-34% -$6.7M ﹤0.01% 1447
2015
Q3 		$23.4M Buy
4,660,314
+305,711
+7% +$1.75M 0.01% 1065
2015
Q2 		$28M Buy
4,354,603
+97,335
+2% +$652K 0.01% 1075
2015
Q1 		$29.9M Buy
4,257,268
+676,728
+19% +$4.9M 0.01% 1030
2014
Q4 		$27.6M Buy
3,580,540
+1,021,113
+40% +$8.08M 0.01% 1056
2014
Q3 		$19.1M Sell
2,559,427
-562,770
-18% -$5.22M 0.01% 1204
2014
Q2 		$30.2M Sell
3,122,197
-127,220
-4% -$1.13M 0.01% 1040
2014
Q1 		$27M Buy
3,249,417
+734,540
+29% +$6.3M 0.01% 1075
2013
Q4 		$21.2M Buy
2,514,877
+639,335
+34% +$5.39M 0.01% 1159
2013
Q3 		$14.9M Buy
1,875,542
+559,118
+42% +$4.49M 0.01% 1271
2013
Q2 		$10.2M Buy
+1,316,424
New +$10.3M ﹤0.01% 1411

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Invesco's PDLI Position: Q4 2020 in Review

Invesco sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 666,925 shares — an estimated $2.1M sold.

Invesco first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $30.2M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Invesco reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Invesco sold 666,925 PDL BioPharma, Inc. shares in Q4 2020, an estimated $2.1M.
  • Invesco first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
  • Invesco's PDL BioPharma, Inc. position peaked at $30.2M in Q2 2014.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Invesco's 13F filing for Q4 2020, filed 16 Feb 2021.